Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

17.03
+0.02000.12%
Post-market: 17.030.00000.00%16:10 EDT
Volume:332.38K
Turnover:5.66M
Market Cap:882.64M
PE:16.30
High:17.07
Open:17.02
Low:17.00
Close:17.01
52wk High:21.03
52wk Low:13.08
Shares:51.83M
Float Shares:25.78M
Volume Ratio:0.89
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.05
EPS(LYR):2.06
ROE:20.91%
ROA:1.33%
PB:3.05
PE(LYR):8.27

Loading ...

BUZZ-Theravance falls as co weighs options including possible sale after drug trial failure

Reuters
·
Mar 03

Theravance to Cut 50% of Workforce in Cost-Savings Push, Wind Down Late-Stage Program

Dow Jones
·
Mar 03

Theravance Biopharma falls 28% to $13.55 in pre-market trading

TIPRANKS
·
Mar 03

Theravance Biopharma implements cost reduction actions after study results

TIPRANKS
·
Mar 03

Theravance Biopharma Restructures After Ampreloxetine Trial Failure

TIPRANKS
·
Mar 03

Theravance Biopharma Shares Fall 28% Premarket After Blood Pressure Drug Does Not Meet Goal in Late-Stage Trial, Co Plans Strategic Review

THOMSON REUTERS
·
Mar 03

Theravance considers possible sale after drug trial setback

Reuters
·
Mar 03

Theravance Biopharma trading halted, news pending

TIPRANKS
·
Mar 03

BRIEF-Theravance Biopharma Reports Phase 3 Cypress Study Did Not Meet Primary Endpoint Board Accelerates Strategic Review And Announces Cost Reduction Actions

Reuters
·
Mar 03

Theravance Biopharma launches restructuring to cut costs by 60%

Reuters
·
Mar 03

Theravance Biopharma Inc: Strategic Review Committee Accelerating Ongoing Efforts to Evaluate Alternatives to Maximize Shareholder Value

THOMSON REUTERS
·
Mar 03

Theravance Biopharma Inc: Reduction Includes Complete Wind-Down of R&D Organization and a Decrease of Approximately 50% in G&a Employees

THOMSON REUTERS
·
Mar 03

Theravance Biopharma Inc: Restructuring Expected to Result in Company Generating Approximately $60 - $70 Mln of Annualized Cash Flow

THOMSON REUTERS
·
Mar 03

Theravance Biopharma Inc: Organizational Restructuring to Reduce Cost Base by Approximately 60%

THOMSON REUTERS
·
Mar 03

NASDAQ TRADE HALT HALT NEWS PENDING AT 08:26 AM

Reuters
·
Mar 03

Theravance Biopharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 02